Nothing Special   »   [go: up one dir, main page]

EA201300843A1 - CARBAMOILPHENYL DERIVATIVES FOR STOPPING, PREVENTION AND PREVENTION OF BLEEDING OR STRENGTHENING OF THE HEMOSTASIS SYSTEM - Google Patents

CARBAMOILPHENYL DERIVATIVES FOR STOPPING, PREVENTION AND PREVENTION OF BLEEDING OR STRENGTHENING OF THE HEMOSTASIS SYSTEM

Info

Publication number
EA201300843A1
EA201300843A1 EA201300843A EA201300843A EA201300843A1 EA 201300843 A1 EA201300843 A1 EA 201300843A1 EA 201300843 A EA201300843 A EA 201300843A EA 201300843 A EA201300843 A EA 201300843A EA 201300843 A1 EA201300843 A1 EA 201300843A1
Authority
EA
Eurasian Patent Office
Prior art keywords
bleeding
prevention
disorders
stopping
blood coagulation
Prior art date
Application number
EA201300843A
Other languages
Russian (ru)
Inventor
Арсений Валерьевич Айбушев
Фазоил Иноятович АТАУЛЛАХАНОВ
Владимир Николаевич КОЛЯДКО
Дмитрий Викторович МАЛАХОВ
Михаил Александрович ПАНТЕЛЕЕВ
Дмитрий Николаевич ТАРАСОВ
Дмитрий Геннадьевич ТОВБИН
Original Assignee
Арсений Валерьевич Айбушев
Фазоил Иноятович АТАУЛЛАХАНОВ
Владимир Николаевич КОЛЯДКО
Дмитрий Викторович МАЛАХОВ
Михаил Александрович ПАНТЕЛЕЕВ
Дмитрий Николаевич ТАРАСОВ
Дмитрий Геннадьевич ТОВБИН
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Арсений Валерьевич Айбушев, Фазоил Иноятович АТАУЛЛАХАНОВ, Владимир Николаевич КОЛЯДКО, Дмитрий Викторович МАЛАХОВ, Михаил Александрович ПАНТЕЛЕЕВ, Дмитрий Николаевич ТАРАСОВ, Дмитрий Геннадьевич ТОВБИН filed Critical Арсений Валерьевич Айбушев
Priority to EA201300843A priority Critical patent/EA201300843A1/en
Priority to PCT/RU2014/000574 priority patent/WO2015016750A1/en
Publication of EA201300843A1 publication Critical patent/EA201300843A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/38—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/40—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Данное изобретение относится к новому классу соединений для остановки, предотвращения и профилактики кровотечений или усиления системы гемостаза. Новые соединения, описанные в изобретении, их фармацевтически приемлемые соли и/или их фармацевтически приемлемым композиции могут использоваться для остановки, предотвращения и профилактики кровотечений у человека и других млекопитающих, которые могут быть следствием гипокоагуляционного состояния системы свертывания крови, нарушения свертываемости крови, гематологических расстройств, геморрагических расстройств, гемофилий, дефицита фактора VII, медикаментозного лечения, травмы, заболевания, нарушений, связанных с кровоточивостью, хирургического вмешательства, гипотермии, менструации и беременности и ряда других болезней у человека и млекопитающих, связанных со свертываемостью крови.This invention relates to a new class of compounds for stopping, preventing and preventing bleeding or enhancing the hemostatic system. The new compounds described in the invention, their pharmaceutically acceptable salts and / or their pharmaceutically acceptable compositions can be used to stop, prevent and prevent bleeding in humans and other mammals, which may be due to the hypocoagulation state of the blood coagulation system, blood coagulation disorders, hematological disorders, hemorrhagic disorders, hemophilia, factor VII deficiency, drug treatment, trauma, disease, bleeding disorders, surgical intervention, hypothermia, menstruation and pregnancy, and a number of other diseases in humans and mammals associated with blood coagulation.

EA201300843A 2013-08-01 2013-08-01 CARBAMOILPHENYL DERIVATIVES FOR STOPPING, PREVENTION AND PREVENTION OF BLEEDING OR STRENGTHENING OF THE HEMOSTASIS SYSTEM EA201300843A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EA201300843A EA201300843A1 (en) 2013-08-01 2013-08-01 CARBAMOILPHENYL DERIVATIVES FOR STOPPING, PREVENTION AND PREVENTION OF BLEEDING OR STRENGTHENING OF THE HEMOSTASIS SYSTEM
PCT/RU2014/000574 WO2015016750A1 (en) 2013-08-01 2014-07-30 Carbamoylphenyl derivatives for stopping, avoiding and preventing bleeding or for strengthening the hemostatic system

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EA201300843A EA201300843A1 (en) 2013-08-01 2013-08-01 CARBAMOILPHENYL DERIVATIVES FOR STOPPING, PREVENTION AND PREVENTION OF BLEEDING OR STRENGTHENING OF THE HEMOSTASIS SYSTEM

Publications (1)

Publication Number Publication Date
EA201300843A1 true EA201300843A1 (en) 2015-04-30

Family

ID=52432155

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201300843A EA201300843A1 (en) 2013-08-01 2013-08-01 CARBAMOILPHENYL DERIVATIVES FOR STOPPING, PREVENTION AND PREVENTION OF BLEEDING OR STRENGTHENING OF THE HEMOSTASIS SYSTEM

Country Status (2)

Country Link
EA (1) EA201300843A1 (en)
WO (1) WO2015016750A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109180573A (en) * 2018-09-17 2019-01-11 珠海润都制药股份有限公司 A kind of preparation method of betrixaban intermediate

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002510313A (en) * 1997-06-26 2002-04-02 イーライ・リリー・アンド・カンパニー Antithrombotic substance
WO2001064643A2 (en) * 2000-02-29 2001-09-07 Cor Therapeutics, Inc. BENZAMIDES AND RELATED INHIBITORS OF FACTOR Xa
US7030141B2 (en) * 2001-11-29 2006-04-18 Christopher Franklin Bigge Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade
WO2003048081A2 (en) * 2001-12-04 2003-06-12 Bristol-Myers Squibb Company Glycinamides as factor xa inhibitors
AU2006325754B2 (en) * 2005-12-14 2012-04-12 Bristol-Myers Squibb Company Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor XIa inhibitors

Also Published As

Publication number Publication date
WO2015016750A1 (en) 2015-02-05

Similar Documents

Publication Publication Date Title
BR112015001419A2 (en) compound, pharmaceutical composition, and methods for inhibiting romk in a patient, causing diuresis, natriuresis, or both, and for treating one or more disorders.
BR112015009948A8 (en) Activin-actrii antagonists, uses thereof for treating bone diseases and other disorders, and method for monitoring the effectiveness of treating or preventing a bone disease and other disorders
BR112012016633A2 (en) dry powder pharmaceutical composition and wound treatment method.
BR112015003188A2 (en) COMPOUND, PHARMACEUTICAL COMPOSITION, COMPOUND USE, AND METHOD FOR TREATMENT OF A RORGAMMAT-MEDIATED DISEASE OR CONDITION IN A PATIENT
BR112015012197A8 (en) cdk mtor inhibitor uses, and pharmaceutical combination comprising the same
BR112013025517A2 (en) use of substituted 2,3-dihydroimidazo [1,2-c] quinazolines
BR112015019039A8 (en) fluorinated integrin antagonist compounds, a pharmaceutical composition comprising said compounds and their use to treat or prevent an av integrin mediated disease or condition
BR112015007814A2 (en) diagnosis, prevention and treatment of joint disease
PH12016500828A1 (en) (aza) pyridopyrazolopyrimidinones and indazolopyrimidinones as inhibitors of fibrinolysis
BR112016009954A2 (en) therapy for the treatment or prevention of conditions associated with hypocoagulation bleeding
EA201791898A1 (en) NEW ANTIBODIES CONNECTING WITH TFPI AND CONTAINING THEIR COMPOSITION
BR112013022217A2 (en) pharmaceutical composition, preventive treatment method of a hemorrhagic syndrome in a patient with haemophilia a or b and method of treating a hemorrhagic accident in a patient with haemophilia a or b
Shehata et al. Topical tranexamic acid versus hot saline for field quality during endoscopic sinus surgery
TN2016000250A1 (en) Substituted piperidinyl-tetrahydroquinolines and their use as alpha-2c adrenoreceptor antagonists.
WO2013028070A3 (en) Compounds for use in boosting coagulation
BR112018010052A2 (en) peptides with antiangiogenic, anti-lymphogenic and antiedemic properties and nanoparticle formulations
BR112015022849A2 (en) nitroxoline base addition salts and uses thereof
MX2017005586A (en) Piperidinylpyrazolopyrimidinones and their use.
CL2009002204A1 (en) Biocompatible intravenous composition comprising a coagulation factor included in alginic acid microparticles or salts thereof.
WO2012103512A3 (en) Expanded utility of red cell-derived microparticles (rmp) for treatment of bleeding
JP2013538863A5 (en)
EA201300843A1 (en) CARBAMOILPHENYL DERIVATIVES FOR STOPPING, PREVENTION AND PREVENTION OF BLEEDING OR STRENGTHENING OF THE HEMOSTASIS SYSTEM
MX2018013203A (en) Cyclodextrins as procoagulants.
BR112015013215A2 (en) slurp-1 protein for use in the manufacture of eye disease medications
MX2013008992A (en) Pharmaceutical composition with anti-inflammatory agents and production process thereof.